Public Act 100-0789
 
SB2341 EnrolledLRB100 17957 MRW 33141 b

    AN ACT concerning criminal law.
 
    Be it enacted by the People of the State of Illinois,
represented in the General Assembly:
 
    Section 5. The Illinois Controlled Substances Act is
amended by changing Sections 102 and 204 as follows:
 
    (720 ILCS 570/102)  (from Ch. 56 1/2, par. 1102)
    Sec. 102. Definitions. As used in this Act, unless the
context otherwise requires:
    (a) "Addict" means any person who habitually uses any drug,
chemical, substance or dangerous drug other than alcohol so as
to endanger the public morals, health, safety or welfare or who
is so far addicted to the use of a dangerous drug or controlled
substance other than alcohol as to have lost the power of self
control with reference to his or her addiction.
    (b) "Administer" means the direct application of a
controlled substance, whether by injection, inhalation,
ingestion, or any other means, to the body of a patient,
research subject, or animal (as defined by the Humane
Euthanasia in Animal Shelters Act) by:
        (1) a practitioner (or, in his or her presence, by his
    or her authorized agent),
        (2) the patient or research subject pursuant to an
    order, or
        (3) a euthanasia technician as defined by the Humane
    Euthanasia in Animal Shelters Act.
    (c) "Agent" means an authorized person who acts on behalf
of or at the direction of a manufacturer, distributor,
dispenser, prescriber, or practitioner. It does not include a
common or contract carrier, public warehouseman or employee of
the carrier or warehouseman.
    (c-1) "Anabolic Steroids" means any drug or hormonal
substance, chemically and pharmacologically related to
testosterone (other than estrogens, progestins,
corticosteroids, and dehydroepiandrosterone), and includes:
    (i) 3[beta],17-dihydroxy-5a-androstane, 
    (ii) 3[alpha],17[beta]-dihydroxy-5a-androstane, 
    (iii) 5[alpha]-androstan-3,17-dione, 
    (iv) 1-androstenediol (3[beta], 
        17[beta]-dihydroxy-5[alpha]-androst-1-ene), 
    (v) 1-androstenediol (3[alpha], 
        17[beta]-dihydroxy-5[alpha]-androst-1-ene), 
    (vi) 4-androstenediol  
        (3[beta],17[beta]-dihydroxy-androst-4-ene), 
    (vii) 5-androstenediol  
        (3[beta],17[beta]-dihydroxy-androst-5-ene), 
    (viii) 1-androstenedione  
        ([5alpha]-androst-1-en-3,17-dione), 
    (ix) 4-androstenedione  
        (androst-4-en-3,17-dione), 
    (x) 5-androstenedione  
        (androst-5-en-3,17-dione), 
    (xi) bolasterone (7[alpha],17a-dimethyl-17[beta]- 
        hydroxyandrost-4-en-3-one), 
    (xii) boldenone (17[beta]-hydroxyandrost- 
        1,4,-diene-3-one), 
    (xiii) boldione (androsta-1,4- 
        diene-3,17-dione), 
    (xiv) calusterone (7[beta],17[alpha]-dimethyl-17 
        [beta]-hydroxyandrost-4-en-3-one), 
    (xv) clostebol (4-chloro-17[beta]- 
        hydroxyandrost-4-en-3-one), 
    (xvi) dehydrochloromethyltestosterone (4-chloro- 
        17[beta]-hydroxy-17[alpha]-methyl- 
        androst-1,4-dien-3-one), 
    (xvii) desoxymethyltestosterone 
    (17[alpha]-methyl-5[alpha] 
        -androst-2-en-17[beta]-ol)(a.k.a., madol), 
    (xviii) [delta]1-dihydrotestosterone (a.k.a.  
        '1-testosterone') (17[beta]-hydroxy- 
        5[alpha]-androst-1-en-3-one), 
    (xix) 4-dihydrotestosterone (17[beta]-hydroxy- 
        androstan-3-one), 
    (xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl- 
        5[alpha]-androstan-3-one), 
    (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]- 
        hydroxyestr-4-ene), 
    (xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl- 
        1[beta],17[beta]-dihydroxyandrost-4-en-3-one), 
    (xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha], 
        17[beta]-dihydroxyandrost-1,4-dien-3-one), 
    (xxiv) furazabol (17[alpha]-methyl-17[beta]- 
        hydroxyandrostano[2,3-c]-furazan), 
    (xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one, ) 
    (xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy- 
        androst-4-en-3-one), 
    (xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]- 
        dihydroxy-estr-4-en-3-one), 
    (xxviii) mestanolone (17[alpha]-methyl-17[beta]- 
        hydroxy-5-androstan-3-one), 
    (xxix) mesterolone (1amethyl-17[beta]-hydroxy- 
        [5a]-androstan-3-one), 
    (xxx) methandienone (17[alpha]-methyl-17[beta]- 
        hydroxyandrost-1,4-dien-3-one), 
    (xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]- 
        dihydroxyandrost-5-ene), 
    (xxxii) methenolone (1-methyl-17[beta]-hydroxy- 
        5[alpha]-androst-1-en-3-one), 
    (xxxiii) 17[alpha]-methyl-3[beta], 17[beta]- 
        dihydroxy-5a-androstane)
    (xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy 
        -5a-androstane)
    (xxxv) 17[alpha]-methyl-3[beta],17[beta]- 
        dihydroxyandrost-4-ene), 
    (xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]- 
        methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one), 
    (xxxvii) methyldienolone (17[alpha]-methyl-17[beta]- 
        hydroxyestra-4,9(10)-dien-3-one), 
    (xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]- 
        hydroxyestra-4,9-11-trien-3-one), 
    (xxxix) methyltestosterone (17[alpha]-methyl-17[beta]- 
        hydroxyandrost-4-en-3-one), 
    (xl) mibolerone (7[alpha],17a-dimethyl-17[beta]- 
        hydroxyestr-4-en-3-one), 
    (xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone  
        (17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]- 
        androst-1-en-3-one)(a.k.a. '17-[alpha]-methyl- 
        1-testosterone'), 
    (xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one), 
    (xliii) 19-nor-4-androstenediol (3[beta], 17[beta]- 
        dihydroxyestr-4-ene), 
    (xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]- 
        dihydroxyestr-4-ene), 
    (xlv) 19-nor-5-androstenediol (3[beta], 17[beta]- 
        dihydroxyestr-5-ene), 
    (xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]- 
        dihydroxyestr-5-ene), 
    (xlvii) 19-nor-4,9(10)-androstadienedione  
        (estra-4,9(10)-diene-3,17-dione), 
    (xlviii) 19-nor-4-androstenedione (estr-4- 
        en-3,17-dione), 
    (xlix) 19-nor-5-androstenedione (estr-5- 
        en-3,17-dione), 
    (l) norbolethone (13[beta], 17a-diethyl-17[beta]- 
        hydroxygon-4-en-3-one), 
    (li) norclostebol (4-chloro-17[beta]- 
        hydroxyestr-4-en-3-one), 
    (lii) norethandrolone (17[alpha]-ethyl-17[beta]- 
        hydroxyestr-4-en-3-one), 
    (liii) normethandrolone (17[alpha]-methyl-17[beta]- 
        hydroxyestr-4-en-3-one), 
    (liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy- 
        2-oxa-5[alpha]-androstan-3-one), 
    (lv) oxymesterone (17[alpha]-methyl-4,17[beta]- 
        dihydroxyandrost-4-en-3-one), 
    (lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene- 
        17[beta]-hydroxy-(5[alpha]-androstan-3-one), 
    (lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy- 
        (5[alpha]-androst-2-eno[3,2-c]-pyrazole), 
    (lviii) stenbolone (17[beta]-hydroxy-2-methyl- 
        (5[alpha]-androst-1-en-3-one), 
    (lix) testolactone (13-hydroxy-3-oxo-13,17- 
        secoandrosta-1,4-dien-17-oic 
        acid lactone), 
    (lx) testosterone (17[beta]-hydroxyandrost- 
        4-en-3-one), 
    (lxi) tetrahydrogestrinone (13[beta], 17[alpha]- 
        diethyl-17[beta]-hydroxygon- 
        4,9,11-trien-3-one), 
    (lxii) trenbolone (17[beta]-hydroxyestr-4,9, 
        11-trien-3-one). 
    Any person who is otherwise lawfully in possession of an
anabolic steroid, or who otherwise lawfully manufactures,
distributes, dispenses, delivers, or possesses with intent to
deliver an anabolic steroid, which anabolic steroid is
expressly intended for and lawfully allowed to be administered
through implants to livestock or other nonhuman species, and
which is approved by the Secretary of Health and Human Services
for such administration, and which the person intends to
administer or have administered through such implants, shall
not be considered to be in unauthorized possession or to
unlawfully manufacture, distribute, dispense, deliver, or
possess with intent to deliver such anabolic steroid for
purposes of this Act.
    (d) "Administration" means the Drug Enforcement
Administration, United States Department of Justice, or its
successor agency.
    (d-5) "Clinical Director, Prescription Monitoring Program"
means a Department of Human Services administrative employee
licensed to either prescribe or dispense controlled substances
who shall run the clinical aspects of the Department of Human
Services Prescription Monitoring Program and its Prescription
Information Library.
    (d-10) "Compounding" means the preparation and mixing of
components, excluding flavorings, (1) as the result of a
prescriber's prescription drug order or initiative based on the
prescriber-patient-pharmacist relationship in the course of
professional practice or (2) for the purpose of, or incident
to, research, teaching, or chemical analysis and not for sale
or dispensing. "Compounding" includes the preparation of drugs
or devices in anticipation of receiving prescription drug
orders based on routine, regularly observed dispensing
patterns. Commercially available products may be compounded
for dispensing to individual patients only if both of the
following conditions are met: (i) the commercial product is not
reasonably available from normal distribution channels in a
timely manner to meet the patient's needs and (ii) the
prescribing practitioner has requested that the drug be
compounded.
    (e) "Control" means to add a drug or other substance, or
immediate precursor, to a Schedule whether by transfer from
another Schedule or otherwise.
    (f) "Controlled Substance" means (i) a drug, substance,
immediate precursor, or synthetic drug in the Schedules of
Article II of this Act or (ii) a drug or other substance, or
immediate precursor, designated as a controlled substance by
the Department through administrative rule. The term does not
include distilled spirits, wine, malt beverages, or tobacco, as
those terms are defined or used in the Liquor Control Act of
1934 and the Tobacco Products Tax Act of 1995.
    (f-5) "Controlled substance analog" means a substance:
        (1) the chemical structure of which is substantially
    similar to the chemical structure of a controlled substance
    in Schedule I or II;
        (2) which has a stimulant, depressant, or
    hallucinogenic effect on the central nervous system that is
    substantially similar to or greater than the stimulant,
    depressant, or hallucinogenic effect on the central
    nervous system of a controlled substance in Schedule I or
    II; or
        (3) with respect to a particular person, which such
    person represents or intends to have a stimulant,
    depressant, or hallucinogenic effect on the central
    nervous system that is substantially similar to or greater
    than the stimulant, depressant, or hallucinogenic effect
    on the central nervous system of a controlled substance in
    Schedule I or II.
    (g) "Counterfeit substance" means a controlled substance,
which, or the container or labeling of which, without
authorization bears the trademark, trade name, or other
identifying mark, imprint, number or device, or any likeness
thereof, of a manufacturer, distributor, or dispenser other
than the person who in fact manufactured, distributed, or
dispensed the substance.
    (h) "Deliver" or "delivery" means the actual, constructive
or attempted transfer of possession of a controlled substance,
with or without consideration, whether or not there is an
agency relationship.
    (i) "Department" means the Illinois Department of Human
Services (as successor to the Department of Alcoholism and
Substance Abuse) or its successor agency.
    (j) (Blank).
    (k) "Department of Corrections" means the Department of
Corrections of the State of Illinois or its successor agency.
    (l) "Department of Financial and Professional Regulation"
means the Department of Financial and Professional Regulation
of the State of Illinois or its successor agency.
    (m) "Depressant" means any drug that (i) causes an overall
depression of central nervous system functions, (ii) causes
impaired consciousness and awareness, and (iii) can be
habit-forming or lead to a substance abuse problem, including
but not limited to alcohol, cannabis and its active principles
and their analogs, benzodiazepines and their analogs,
barbiturates and their analogs, opioids (natural and
synthetic) and their analogs, and chloral hydrate and similar
sedative hypnotics.
    (n) (Blank).
    (o) "Director" means the Director of the Illinois State
Police or his or her designated agents.
    (p) "Dispense" means to deliver a controlled substance to
an ultimate user or research subject by or pursuant to the
lawful order of a prescriber, including the prescribing,
administering, packaging, labeling, or compounding necessary
to prepare the substance for that delivery.
    (q) "Dispenser" means a practitioner who dispenses.
    (r) "Distribute" means to deliver, other than by
administering or dispensing, a controlled substance.
    (s) "Distributor" means a person who distributes.
    (t) "Drug" means (1) substances recognized as drugs in the
official United States Pharmacopoeia, Official Homeopathic
Pharmacopoeia of the United States, or official National
Formulary, or any supplement to any of them; (2) substances
intended for use in diagnosis, cure, mitigation, treatment, or
prevention of disease in man or animals; (3) substances (other
than food) intended to affect the structure of any function of
the body of man or animals and (4) substances intended for use
as a component of any article specified in clause (1), (2), or
(3) of this subsection. It does not include devices or their
components, parts, or accessories.
    (t-3) "Electronic health record" or "EHR" means an
electronic record of health-related information on an
individual that is created, gathered, managed, and consulted by
authorized health care clinicians and staff.
    (t-4) "Emergency medical services personnel" has the
meaning ascribed to it in the Emergency Medical Services (EMS)
Systems Act.
    (t-5) "Euthanasia agency" means an entity certified by the
Department of Financial and Professional Regulation for the
purpose of animal euthanasia that holds an animal control
facility license or animal shelter license under the Animal
Welfare Act. A euthanasia agency is authorized to purchase,
store, possess, and utilize Schedule II nonnarcotic and
Schedule III nonnarcotic drugs for the sole purpose of animal
euthanasia.
    (t-10) "Euthanasia drugs" means Schedule II or Schedule III
substances (nonnarcotic controlled substances) that are used
by a euthanasia agency for the purpose of animal euthanasia.
    (u) "Good faith" means the prescribing or dispensing of a
controlled substance by a practitioner in the regular course of
professional treatment to or for any person who is under his or
her treatment for a pathology or condition other than that
individual's physical or psychological dependence upon or
addiction to a controlled substance, except as provided herein:
and application of the term to a pharmacist shall mean the
dispensing of a controlled substance pursuant to the
prescriber's order which in the professional judgment of the
pharmacist is lawful. The pharmacist shall be guided by
accepted professional standards including, but not limited to
the following, in making the judgment:
        (1) lack of consistency of prescriber-patient
    relationship,
        (2) frequency of prescriptions for same drug by one
    prescriber for large numbers of patients,
        (3) quantities beyond those normally prescribed,
        (4) unusual dosages (recognizing that there may be
    clinical circumstances where more or less than the usual
    dose may be used legitimately),
        (5) unusual geographic distances between patient,
    pharmacist and prescriber,
        (6) consistent prescribing of habit-forming drugs.
    (u-0.5) "Hallucinogen" means a drug that causes markedly
altered sensory perception leading to hallucinations of any
type.
    (u-1) "Home infusion services" means services provided by a
pharmacy in compounding solutions for direct administration to
a patient in a private residence, long-term care facility, or
hospice setting by means of parenteral, intravenous,
intramuscular, subcutaneous, or intraspinal infusion.
    (u-5) "Illinois State Police" means the State Police of the
State of Illinois, or its successor agency.
    (v) "Immediate precursor" means a substance:
        (1) which the Department has found to be and by rule
    designated as being a principal compound used, or produced
    primarily for use, in the manufacture of a controlled
    substance;
        (2) which is an immediate chemical intermediary used or
    likely to be used in the manufacture of such controlled
    substance; and
        (3) the control of which is necessary to prevent,
    curtail or limit the manufacture of such controlled
    substance.
    (w) "Instructional activities" means the acts of teaching,
educating or instructing by practitioners using controlled
substances within educational facilities approved by the State
Board of Education or its successor agency.
    (x) "Local authorities" means a duly organized State,
County or Municipal peace unit or police force.
    (y) "Look-alike substance" means a substance, other than a
controlled substance which (1) by overall dosage unit
appearance, including shape, color, size, markings or lack
thereof, taste, consistency, or any other identifying physical
characteristic of the substance, would lead a reasonable person
to believe that the substance is a controlled substance, or (2)
is expressly or impliedly represented to be a controlled
substance or is distributed under circumstances which would
lead a reasonable person to believe that the substance is a
controlled substance. For the purpose of determining whether
the representations made or the circumstances of the
distribution would lead a reasonable person to believe the
substance to be a controlled substance under this clause (2) of
subsection (y), the court or other authority may consider the
following factors in addition to any other factor that may be
relevant:
        (a) statements made by the owner or person in control
    of the substance concerning its nature, use or effect;
        (b) statements made to the buyer or recipient that the
    substance may be resold for profit;
        (c) whether the substance is packaged in a manner
    normally used for the illegal distribution of controlled
    substances;
        (d) whether the distribution or attempted distribution
    included an exchange of or demand for money or other
    property as consideration, and whether the amount of the
    consideration was substantially greater than the
    reasonable retail market value of the substance.
    Clause (1) of this subsection (y) shall not apply to a
noncontrolled substance in its finished dosage form that was
initially introduced into commerce prior to the initial
introduction into commerce of a controlled substance in its
finished dosage form which it may substantially resemble.
    Nothing in this subsection (y) prohibits the dispensing or
distributing of noncontrolled substances by persons authorized
to dispense and distribute controlled substances under this
Act, provided that such action would be deemed to be carried
out in good faith under subsection (u) if the substances
involved were controlled substances.
    Nothing in this subsection (y) or in this Act prohibits the
manufacture, preparation, propagation, compounding,
processing, packaging, advertising or distribution of a drug or
drugs by any person registered pursuant to Section 510 of the
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).
    (y-1) "Mail-order pharmacy" means a pharmacy that is
located in a state of the United States that delivers,
dispenses or distributes, through the United States Postal
Service or other common carrier, to Illinois residents, any
substance which requires a prescription.
    (z) "Manufacture" means the production, preparation,
propagation, compounding, conversion or processing of a
controlled substance other than methamphetamine, either
directly or indirectly, by extraction from substances of
natural origin, or independently by means of chemical
synthesis, or by a combination of extraction and chemical
synthesis, and includes any packaging or repackaging of the
substance or labeling of its container, except that this term
does not include:
        (1) by an ultimate user, the preparation or compounding
    of a controlled substance for his or her own use; or
        (2) by a practitioner, or his or her authorized agent
    under his or her supervision, the preparation,
    compounding, packaging, or labeling of a controlled
    substance:
            (a) as an incident to his or her administering or
        dispensing of a controlled substance in the course of
        his or her professional practice; or
            (b) as an incident to lawful research, teaching or
        chemical analysis and not for sale.
    (z-1) (Blank).
    (z-5) "Medication shopping" means the conduct prohibited
under subsection (a) of Section 314.5 of this Act.
    (z-10) "Mid-level practitioner" means (i) a physician
assistant who has been delegated authority to prescribe through
a written delegation of authority by a physician licensed to
practice medicine in all of its branches, in accordance with
Section 7.5 of the Physician Assistant Practice Act of 1987,
(ii) an advanced practice registered nurse who has been
delegated authority to prescribe through a written delegation
of authority by a physician licensed to practice medicine in
all of its branches or by a podiatric physician, in accordance
with Section 65-40 of the Nurse Practice Act, (iii) an advanced
practice registered nurse certified as a nurse practitioner,
nurse midwife, or clinical nurse specialist who has been
granted authority to prescribe by a hospital affiliate in
accordance with Section 65-45 of the Nurse Practice Act, (iv)
an animal euthanasia agency, or (v) a prescribing psychologist.
    (aa) "Narcotic drug" means any of the following, whether
produced directly or indirectly by extraction from substances
of vegetable origin, or independently by means of chemical
synthesis, or by a combination of extraction and chemical
synthesis:
        (1) opium, opiates, derivatives of opium and opiates,
    including their isomers, esters, ethers, salts, and salts
    of isomers, esters, and ethers, whenever the existence of
    such isomers, esters, ethers, and salts is possible within
    the specific chemical designation; however the term
    "narcotic drug" does not include the isoquinoline
    alkaloids of opium;
        (2) (blank);
        (3) opium poppy and poppy straw;
        (4) coca leaves, except coca leaves and extracts of
    coca leaves from which substantially all of the cocaine and
    ecgonine, and their isomers, derivatives and salts, have
    been removed;
        (5) cocaine, its salts, optical and geometric isomers,
    and salts of isomers;
        (6) ecgonine, its derivatives, their salts, isomers,
    and salts of isomers;
        (7) any compound, mixture, or preparation which
    contains any quantity of any of the substances referred to
    in subparagraphs (1) through (6).
    (bb) "Nurse" means a registered nurse licensed under the
Nurse Practice Act.
    (cc) (Blank).
    (dd) "Opiate" means any substance having an addiction
forming or addiction sustaining liability similar to morphine
or being capable of conversion into a drug having addiction
forming or addiction sustaining liability.
    (ee) "Opium poppy" means the plant of the species Papaver
somniferum L., except its seeds.
    (ee-5) "Oral dosage" means a tablet, capsule, elixir, or
solution or other liquid form of medication intended for
administration by mouth, but the term does not include a form
of medication intended for buccal, sublingual, or transmucosal
administration.
    (ff) "Parole and Pardon Board" means the Parole and Pardon
Board of the State of Illinois or its successor agency.
    (gg) "Person" means any individual, corporation,
mail-order pharmacy, government or governmental subdivision or
agency, business trust, estate, trust, partnership or
association, or any other entity.
    (hh) "Pharmacist" means any person who holds a license or
certificate of registration as a registered pharmacist, a local
registered pharmacist or a registered assistant pharmacist
under the Pharmacy Practice Act.
    (ii) "Pharmacy" means any store, ship or other place in
which pharmacy is authorized to be practiced under the Pharmacy
Practice Act.
    (ii-5) "Pharmacy shopping" means the conduct prohibited
under subsection (b) of Section 314.5 of this Act.
    (ii-10) "Physician" (except when the context otherwise
requires) means a person licensed to practice medicine in all
of its branches.
    (jj) "Poppy straw" means all parts, except the seeds, of
the opium poppy, after mowing.
    (kk) "Practitioner" means a physician licensed to practice
medicine in all its branches, dentist, optometrist, podiatric
physician, veterinarian, scientific investigator, pharmacist,
physician assistant, advanced practice registered nurse,
licensed practical nurse, registered nurse, emergency medical
services personnel, hospital, laboratory, or pharmacy, or
other person licensed, registered, or otherwise lawfully
permitted by the United States or this State to distribute,
dispense, conduct research with respect to, administer or use
in teaching or chemical analysis, a controlled substance in the
course of professional practice or research.
    (ll) "Pre-printed prescription" means a written
prescription upon which the designated drug has been indicated
prior to the time of issuance; the term does not mean a written
prescription that is individually generated by machine or
computer in the prescriber's office.
    (mm) "Prescriber" means a physician licensed to practice
medicine in all its branches, dentist, optometrist,
prescribing psychologist licensed under Section 4.2 of the
Clinical Psychologist Licensing Act with prescriptive
authority delegated under Section 4.3 of the Clinical
Psychologist Licensing Act, podiatric physician, or
veterinarian who issues a prescription, a physician assistant
who issues a prescription for a controlled substance in
accordance with Section 303.05, a written delegation, and a
written collaborative agreement required under Section 7.5 of
the Physician Assistant Practice Act of 1987, an advanced
practice registered nurse with prescriptive authority
delegated under Section 65-40 of the Nurse Practice Act and in
accordance with Section 303.05, a written delegation, and a
written collaborative agreement under Section 65-35 of the
Nurse Practice Act, an advanced practice registered nurse
certified as a nurse practitioner, nurse midwife, or clinical
nurse specialist who has been granted authority to prescribe by
a hospital affiliate in accordance with Section 65-45 of the
Nurse Practice Act and in accordance with Section 303.05, or an
advanced practice registered nurse certified as a nurse
practitioner, nurse midwife, or clinical nurse specialist who
has full practice authority pursuant to Section 65-43 of the
Nurse Practice Act.
    (nn) "Prescription" means a written, facsimile, or oral
order, or an electronic order that complies with applicable
federal requirements, of a physician licensed to practice
medicine in all its branches, dentist, podiatric physician or
veterinarian for any controlled substance, of an optometrist in
accordance with Section 15.1 of the Illinois Optometric
Practice Act of 1987, of a prescribing psychologist licensed
under Section 4.2 of the Clinical Psychologist Licensing Act
with prescriptive authority delegated under Section 4.3 of the
Clinical Psychologist Licensing Act, of a physician assistant
for a controlled substance in accordance with Section 303.05, a
written delegation, and a written collaborative agreement
required under Section 7.5 of the Physician Assistant Practice
Act of 1987, of an advanced practice registered nurse with
prescriptive authority delegated under Section 65-40 of the
Nurse Practice Act who issues a prescription for a controlled
substance in accordance with Section 303.05, a written
delegation, and a written collaborative agreement under
Section 65-35 of the Nurse Practice Act, of an advanced
practice registered nurse certified as a nurse practitioner,
nurse midwife, or clinical nurse specialist who has been
granted authority to prescribe by a hospital affiliate in
accordance with Section 65-45 of the Nurse Practice Act and in
accordance with Section 303.05 when required by law, or of an
advanced practice registered nurse certified as a nurse
practitioner, nurse midwife, or clinical nurse specialist who
has full practice authority pursuant to Section 65-43 of the
Nurse Practice Act.
    (nn-5) "Prescription Information Library" (PIL) means an
electronic library that contains reported controlled substance
data.
    (nn-10) "Prescription Monitoring Program" (PMP) means the
entity that collects, tracks, and stores reported data on
controlled substances and select drugs pursuant to Section 316.
    (oo) "Production" or "produce" means manufacture,
planting, cultivating, growing, or harvesting of a controlled
substance other than methamphetamine.
    (pp) "Registrant" means every person who is required to
register under Section 302 of this Act.
    (qq) "Registry number" means the number assigned to each
person authorized to handle controlled substances under the
laws of the United States and of this State.
    (qq-5) "Secretary" means, as the context requires, either
the Secretary of the Department or the Secretary of the
Department of Financial and Professional Regulation, and the
Secretary's designated agents.
    (rr) "State" includes the State of Illinois and any state,
district, commonwealth, territory, insular possession thereof,
and any area subject to the legal authority of the United
States of America.
    (rr-5) "Stimulant" means any drug that (i) causes an
overall excitation of central nervous system functions, (ii)
causes impaired consciousness and awareness, and (iii) can be
habit-forming or lead to a substance abuse problem, including
but not limited to amphetamines and their analogs,
methylphenidate and its analogs, cocaine, and phencyclidine
and its analogs.
    (rr-10) "Synthetic drug" includes, but is not limited to,
any synthetic cannabinoids or piperazines or any synthetic
cathinones as provided for in Schedule I.
    (ss) "Ultimate user" means a person who lawfully possesses
a controlled substance for his or her own use or for the use of
a member of his or her household or for administering to an
animal owned by him or her or by a member of his or her
household.
(Source: P.A. 99-78, eff. 7-20-15; 99-173, eff. 7-29-15;
99-371, eff. 1-1-16; 99-480, eff. 9-9-15; 99-642, eff. 7-28-16;
100-280, eff. 1-1-18; 100-453, eff. 8-25-17; 100-513, eff.
1-1-18; revised 10-6-17.)
 
    (720 ILCS 570/204)  (from Ch. 56 1/2, par. 1204)
    Sec. 204. (a) The controlled substances listed in this
Section are included in Schedule I.
    (b) Unless specifically excepted or unless listed in
another schedule, any of the following opiates, including their
isomers, esters, ethers, salts, and salts of isomers, esters,
and ethers, whenever the existence of such isomers, esters,
ethers and salts is possible within the specific chemical
designation:
        (1) Acetylmethadol;
        (1.1) Acetyl-alpha-methylfentanyl
    (N-[1-(1-methyl-2-phenethyl)-
    4-piperidinyl]-N-phenylacetamide);
        (2) Allylprodine;
        (3) Alphacetylmethadol, except
    levo-alphacetylmethadol (also known as levo-alpha-
    acetylmethadol, levomethadyl acetate, or LAAM);
        (4) Alphameprodine;
        (5) Alphamethadol;
        (6) Alpha-methylfentanyl
    (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
    propionanilide;  1-(1-methyl-2-phenylethyl)-4-(N-
    propanilido) piperidine;
        (6.1) Alpha-methylthiofentanyl
    (N-[1-methyl-2-(2-thienyl)ethyl-
    4-piperidinyl]-N-phenylpropanamide);
        (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
        (7.1) PEPAP
    (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
        (8) Benzethidine;
        (9) Betacetylmethadol;
        (9.1) Beta-hydroxyfentanyl
    (N-[1-(2-hydroxy-2-phenethyl)-
    4-piperidinyl]-N-phenylpropanamide);
        (10) Betameprodine;
        (11) Betamethadol;
        (12) Betaprodine;
        (13) Clonitazene;
        (14) Dextromoramide;
        (15) Diampromide;
        (16) Diethylthiambutene;
        (17) Difenoxin;
        (18) Dimenoxadol;
        (19) Dimepheptanol;
        (20) Dimethylthiambutene;
        (21) Dioxaphetylbutyrate;
        (22) Dipipanone;
        (23) Ethylmethylthiambutene;
        (24) Etonitazene;
        (25) Etoxeridine;
        (26) Furethidine;
        (27) Hydroxpethidine;
        (28) Ketobemidone;
        (29) Levomoramide;
        (30) Levophenacylmorphan;
        (31) 3-Methylfentanyl
    (N-[3-methyl-1-(2-phenylethyl)-
    4-piperidyl]-N-phenylpropanamide);
        (31.1) 3-Methylthiofentanyl
    (N-[(3-methyl-1-(2-thienyl)ethyl-
    4-piperidinyl]-N-phenylpropanamide);
        (32) Morpheridine;
        (33) Noracymethadol;
        (34) Norlevorphanol;
        (35) Normethadone;
        (36) Norpipanone;
        (36.1) Para-fluorofentanyl
    (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
    4-piperidinyl]propanamide);
        (37) Phenadoxone;
        (38) Phenampromide;
        (39) Phenomorphan;
        (40) Phenoperidine;
        (41) Piritramide;
        (42) Proheptazine;
        (43) Properidine;
        (44) Propiram;
        (45) Racemoramide;
        (45.1) Thiofentanyl
    (N-phenyl-N-[1-(2-thienyl)ethyl-
    4-piperidinyl]-propanamide);
        (46) Tilidine;
        (47) Trimeperidine;
        (48) Beta-hydroxy-3-methylfentanyl (other name:
    N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
    N-phenylpropanamide);
        (49) Furanyl fentanyl (FU-F);
        (50) Butyryl fentanyl;
        (51) Valeryl fentanyl;
        (52) Acetyl fentanyl;
        (53) Beta-hydroxy-thiofentanyl;
        (54) 3,4-dichloro-N-[2-
    (dimethylamino)cyclohexyl]-N-
    methylbenzamide (U-47700); 
        (55) 4-chloro-N-[1-[2-
    (4-nitrophenyl)ethyl]-2-piperidinylidene]-
    benzenesulfonamide (W-18); 
        (56) 4-chloro-N-[1-(2-phenylethyl)
    -2-piperidinylidene]-benzenesulfonamide (W-15); 
        (57) acrylfentanyl (acryloylfentanyl). 
    (c) Unless specifically excepted or unless listed in
another schedule, any of the following opium derivatives, its
salts, isomers and salts of isomers, whenever the existence of
such salts, isomers and salts of isomers is possible within the
specific chemical designation:
        (1) Acetorphine;
        (2) Acetyldihydrocodeine;
        (3) Benzylmorphine;
        (4) Codeine methylbromide;
        (5) Codeine-N-Oxide;
        (6) Cyprenorphine;
        (7) Desomorphine;
        (8) Diacetyldihydromorphine (Dihydroheroin);
        (9) Dihydromorphine;
        (10) Drotebanol;
        (11) Etorphine (except hydrochloride salt);
        (12) Heroin;
        (13) Hydromorphinol;
        (14) Methyldesorphine;
        (15) Methyldihydromorphine;
        (16) Morphine methylbromide;
        (17) Morphine methylsulfonate;
        (18) Morphine-N-Oxide;
        (19) Myrophine;
        (20) Nicocodeine;
        (21) Nicomorphine;
        (22) Normorphine;
        (23) Pholcodine;
        (24) Thebacon.
    (d) Unless specifically excepted or unless listed in
another schedule, any material, compound, mixture, or
preparation which contains any quantity of the following
hallucinogenic substances, or which contains any of its salts,
isomers and salts of isomers, whenever the existence of such
salts, isomers, and salts of isomers is possible within the
specific chemical designation (for the purposes of this
paragraph only, the term "isomer" includes the optical,
position and geometric isomers):
        (1) 3,4-methylenedioxyamphetamine
    (alpha-methyl,3,4-methylenedioxyphenethylamine,
    methylenedioxyamphetamine, MDA);
        (1.1) Alpha-ethyltryptamine
    (some trade or other names: etryptamine;
    MONASE; alpha-ethyl-1H-indole-3-ethanamine;
    3-(2-aminobutyl)indole; a-ET; and AET);
        (2) 3,4-methylenedioxymethamphetamine (MDMA);
        (2.1) 3,4-methylenedioxy-N-ethylamphetamine
    (also known as: N-ethyl-alpha-methyl-
    3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
    and MDEA);
        (2.2) N-Benzylpiperazine (BZP);
        (2.2-1) Trifluoromethylphenylpiperazine (TFMPP);
        (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);
        (4) 3,4,5-trimethoxyamphetamine (TMA);
        (5) (Blank);
        (6) Diethyltryptamine (DET);
        (7) Dimethyltryptamine (DMT);
        (7.1) 5-Methoxy-diallyltryptamine;
        (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
        (9) Ibogaine  (some trade and other names:
    7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
    6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
    indole; Tabernanthe iboga);
        (10) Lysergic acid diethylamide;
        (10.1) Salvinorin A;
        (10.5) Salvia divinorum (meaning all parts of the plant
    presently classified botanically as Salvia divinorum,
    whether growing or not, the seeds thereof, any extract from
    any part of that plant, and every compound, manufacture,
    salts, isomers, and salts of isomers whenever the existence
    of such salts, isomers, and salts of isomers is possible
    within the specific chemical designation, derivative,
    mixture, or preparation of that plant, its seeds or
    extracts);
        (11) 3,4,5-trimethoxyphenethylamine (Mescaline);
        (12) Peyote (meaning all parts of the plant presently
    classified botanically as Lophophora williamsii Lemaire,
    whether growing or not, the seeds thereof, any extract from
    any part of that plant, and every compound, manufacture,
    salts, derivative, mixture, or preparation of that plant,
    its seeds or extracts);
        (13) N-ethyl-3-piperidyl benzilate (JB 318);
        (14) N-methyl-3-piperidyl benzilate;
        (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
    (also known as N-hydroxy-alpha-methyl-
    3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);
        (15) Parahexyl; some trade or other names:
    3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
    dibenzo (b,d) pyran; Synhexyl;
        (16) Psilocybin;
        (17) Psilocyn;
        (18) Alpha-methyltryptamine (AMT);
        (19) 2,5-dimethoxyamphetamine
    (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);
        (20) 4-bromo-2,5-dimethoxyamphetamine
    (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
    4-bromo-2,5-DMA);
        (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
    Some trade or other names: 2-(4-bromo-
    2,5-dimethoxyphenyl)-1-aminoethane;
    alpha-desmethyl DOB, 2CB, Nexus;
        (21) 4-methoxyamphetamine
    (4-methoxy-alpha-methylphenethylamine;
    paramethoxyamphetamine; PMA);
        (22) (Blank);
        (23) Ethylamine analog of phencyclidine.
    Some trade or other names:
    N-ethyl-1-phenylcyclohexylamine,
    (1-phenylcyclohexyl) ethylamine,
    N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
        (24) Pyrrolidine analog of phencyclidine. Some trade
    or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,
    PHP;
        (25) 5-methoxy-3,4-methylenedioxy-amphetamine;
        (26) 2,5-dimethoxy-4-ethylamphetamine
    (another name: DOET);
        (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
    (another name: TCPy);
        (28) (Blank);
        (29) Thiophene analog of phencyclidine (some trade
    or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
    2-thienyl analog of phencyclidine; TPCP; TCP);
        (29.1) Benzothiophene analog of phencyclidine. Some
    trade or other names: BTCP or benocyclidine;
        (29.2) 3-Methoxyphencyclidine (3-MeO-PCP);
        (30) Bufotenine (some trade or other names:
    3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
    3-(2-dimethylaminoethyl)-5-indolol;
    5-hydroxy-N,N-dimethyltryptamine;
    N,N-dimethylserotonin; mappine);
        (31) (Blank);  
        (32) (Blank);  
        (33) (Blank);  
        (34) (Blank); 
        (34.5) (Blank);  
        (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-
    (2-methyloctan-2-yl)-6a,7, 
    10,10a-tetrahydrobenzo[c]chromen-1-ol
    Some trade or other names: HU-210; 
        (35.5)  (6aS,10aS)-9-(hydroxymethyl)-6,6- 
    dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- 
    tetrahydrobenzo[c]chromen-1-ol, its isomers,  
    salts, and salts of isomers; Some trade or other  
    names: HU-210, Dexanabinol; 
        (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-
    6,6-dimethyl-3-(2-methyloctan-2-yl)- 
    6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
    Some trade or other names: HU-211;
        (37) (Blank);
        (38) (Blank);
        (39) (Blank);
        (40) (Blank);
        (41) (Blank);
        (42) Any compound structurally derived from
    3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane
    by substitution at the nitrogen atom of the indole ring by
    alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
    cycloalkylethyl, aryl halide, alkyl aryl halide,
    1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl whether or not further substituted
    in the indole ring to any extent, whether or not
    substituted in the naphthyl ring to any extent. Examples of
    this structural class include, but are not limited to,
    JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185;
        (43) Any compound structurally derived from
    3-(1-naphthoyl)pyrrole by substitution at the nitrogen
    atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,
    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
    halide, 1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl, whether or not further substituted
    in the pyrrole ring to any extent, whether or not
    substituted in the naphthyl ring to any extent. Examples of
    this structural class include, but are not limited to,
    JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368;
        (44) Any compound structurally derived from
    1-(1-naphthylmethyl)indene by substitution at the
    3-position of the indene ring by alkyl, haloalkyl, alkenyl,
    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
    halide, 1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl whether or not further substituted
    in the indene ring to any extent, whether or not
    substituted in the naphthyl ring to any extent. Examples of
    this structural class include, but are not limited to,
    JWH-176;
        (45) Any compound structurally derived from
    3-phenylacetylindole by substitution at the nitrogen atom
    of the indole ring with alkyl, haloalkyl, alkenyl,
    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
    halide, 1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl, whether or not further substituted
    in the indole ring to any extent, whether or not
    substituted in the phenyl ring to any extent. Examples of
    this structural class include, but are not limited to,
    JWH-167, JWH-250, JWH-251, and RCS-8;
        (46) Any compound structurally derived from
    2-(3-hydroxycyclohexyl)phenol by substitution at the
    5-position of the phenolic ring by alkyl, haloalkyl,
    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl, whether or not substituted in the
    cyclohexyl ring to any extent. Examples of this structural
    class include, but are not limited to, CP 47, 497 and its
    C8 homologue (cannabicyclohexanol);
        (46.1) Any compound structurally derived from
    3-(benzoyl) indole with substitution at the nitrogen atom
    of the indole ring by an alkyl, haloalkyl, alkenyl,
    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
    halide, 1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl group whether or not further
    substituted in the indole ring to any extent and whether or
    not substituted in the phenyl ring to any extent. Examples
    of this structural class include, but are not limited to,
    AM-630, AM-2233, AM-694, Pravadoline (WIN 48,098), and
    RCS-4;
        (47) (Blank);
        (48) (Blank);
        (49) (Blank);
        (50) (Blank);
        (51) (Blank);
        (52) (Blank);
        (53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine.
    Some trade or other names: 2C-T-7;
        (53.1) 4-ethyl-2,5-dimethoxyphenethylamine. Some trade
    or other names: 2C-E;
        (53.2) 2,5-dimethoxy-4-methylphenethylamine. Some
    trade or other names: 2C-D;
        (53.3) 4-chloro-2,5-dimethoxyphenethylamine. Some
    trade or other names: 2C-C;
        (53.4) 4-iodo-2,5-dimethoxyphenethylamine. Some trade
    or other names: 2C-I;
        (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine. Some
    trade or other names: 2C-T-2;
        (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine.
    Some trade or other names: 2C-T-4;
        (53.7) 2,5-dimethoxyphenethylamine. Some trade or
    other names: 2C-H;
        (53.8) 2,5-dimethoxy-4-nitrophenethylamine. Some trade
    or other names: 2C-N;
        (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine. Some
    trade or other names: 2C-P;
        (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine. Some
    trade or other names: 2C-G;
        (53.11) The N-(2-methoxybenzyl) derivative of any 2C
    phenethylamine referred to in subparagraphs (20.1), (53),
    (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7),
    (53.8), (53.9), and (53.10) including, but not limited to,
    25I-NBOMe and 25C-NBOMe;
        (54) 5-Methoxy-N,N-diisopropyltryptamine;
        (55) (Blank);
        (56) (Blank);
        (57) (Blank);
        (58) (Blank);
        (59) 3-cyclopropoylindole with substitution at the
    nitrogen atom of the indole ring by alkyl, haloalkyl,
    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl, whether or not further substituted
    on the indole ring to any extent, whether or not
    substituted on the cyclopropyl ring to any extent:
    including, but not limited to, XLR11, UR144, FUB-144;
        (60) 3-adamantoylindole with substitution at the
    nitrogen atom of the indole ring by alkyl, haloalkyl,
    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl, whether or not further substituted
    on the indole ring to any extent, whether or not
    substituted on the adamantyl ring to any extent: including,
    but not limited to, AB-001;
        (61) N-(adamantyl)-indole-3-carboxamide with
    substitution at the nitrogen atom of the indole ring by
    alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
    cycloalkylethyl, aryl halide, alkyl aryl halide,
    1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl, whether or not further substituted
    on the indole ring to any extent, whether or not
    substituted on the adamantyl ring to any extent: including,
    but not limited to, APICA/2NE-1, STS-135;
        (62) N-(adamantyl)-indazole-3-carboxamide with
    substitution at a nitrogen atom of the indazole ring by
    alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
    cycloalkylethyl, aryl halide, alkyl aryl halide,
    1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl, whether or not further substituted
    on the indazole ring to any extent, whether or not
    substituted on the adamantyl ring to any extent: including,
    but not limited to, AKB48, 5F-AKB48;
        (63) 1H-indole-3-carboxylic acid 8-quinolinyl ester
    with substitution at the nitrogen atom of the indole ring
    by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
    cycloalkylethyl, aryl halide, alkyl aryl halide,
    1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl, whether or not further substituted
    on the indole ring to any extent, whether or not
    substituted on the quinoline ring to any extent: including,
    but not limited to, PB22, 5F-PB22, FUB-PB-22;
        (64) 3-(1-naphthoyl)indazole with substitution at the
    nitrogen atom of the indazole ring by alkyl, haloalkyl,
    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl, whether or not further substituted
    on the indazole ring to any extent, whether or not
    substituted on the naphthyl ring to any extent: including,
    but not limited to, THJ-018, THJ-2201;
        (65) 2-(1-naphthoyl)benzimidazole with substitution at
    the nitrogen atom of the benzimidazole ring by alkyl,
    haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
    aryl halide, alkyl aryl halide,
    1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl, whether or not further substituted
    on the benzimidazole ring to any extent, whether or not
    substituted on the naphthyl ring to any extent: including,
    but not limited to, FUBIMINA;
        (66) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole-
    3-carboxamide with substitution on the nitrogen atom of the
    indazole ring by alkyl, haloalkyl, alkenyl,
    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
    halide, 1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl, whether or not further substituted
    on the indazole ring to any extent: including, but not
    limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA;
        (67) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
    indazole-3-carboxamide with substitution on the nitrogen
    atom of the indazole ring by alkyl, haloalkyl, alkenyl,
    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
    halide, 1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl, whether or not further substituted
    on the indazole ring to any extent: including, but not
    limited to, ADB-PINACA, ADB-FUBINACA;
        (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
    indole-3-carboxamide with substitution on the nitrogen
    atom of the indole ring by alkyl, haloalkyl, alkenyl,
    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
    halide, 1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl, whether or not further substituted
    on the indole ring to any extent: including, but not
    limited to, ADBICA, 5F-ADBICA;
        (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole-
    3-carboxamide with substitution on the nitrogen atom of the
    indole ring by alkyl, haloalkyl, alkenyl,
    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
    halide, 1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl, whether or not further substituted
    on the indole ring to any extent: including, but not
    limited to, ABICA, 5F-ABICA;
        (70) Methyl 2-(1H-indazole-3-carboxamido)-3-
    methylbutanoate with substitution on the nitrogen atom of
    the indazole ring by alkyl, haloalkyl, alkenyl,
    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
    halide, 1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl, whether or not further substituted
    on the indazole ring to any extent: including, but not
    limited to, AMB, 5F-AMB; .
        (71) Methyl 2-(1H-indazole-3-carboxamido)-3,3-
    dimethylbutanoate with substitution on the nitrogen atom
    of the indazole ring by alkyl, haloalkyl, alkenyl,
    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
    halide, 1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl, whether or not further substituted
    on the indazole ring to any extent: including, but not
    limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA;
        (72) Methyl 2-(1H-indole-3-carboxamido)-3-
    methylbutanoate with substitution on the nitrogen atom of
    the indole ring by alkyl, haloalkyl, alkenyl,
    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
    halide, 1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl, whether or not further substituted
    on the indazole ring to any extent: including, but not
    limited to, MMB018, MMB2201, and AMB-CHMICA;
        (73) Methyl 2-(1H-indole-3-carboxamido)-3,3-
    dimethylbutanoate with substitution on the nitrogen atom
    of the indole ring by alkyl, haloalkyl, alkenyl,
    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
    halide, 1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl, whether or not further substituted
    on the indazole ring to any extent: including, but not
    limited to, MDMB-CHMICA;
        (74) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-
    indazole-3-carboxamide with substitution on the nitrogen
    atom of the indazole ring by alkyl, haloalkyl, alkenyl,
    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
    halide, 1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl, whether or not further substituted
    on the indazole ring to any     extent: including, but not
    limited to, APP-CHMINACA, 5-fluoro-APP-PINACA;
        (75) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indole-
    3-carboxamide with substitution on the nitrogen atom of the
    indole ring by alkyl, haloalkyl, alkenyl,
    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
    halide, 1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl, whether or not further substituted
    on the indazole ring to any extent: including, but not
    limited to, APP-PICA and 5-fluoro-APP-PICA;
        (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name
    4-AcO-DMT;
        (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade
    name 5-MeO-MIPT;
        (78) 4-hydroxy Diethyltryptamine (4-HO-DET);
        (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);
        (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
        (81) 4-hydroxy-N-methyl-N-isopropyltryptamine
    (4-HO-MiPT);
        (82) Fluorophenylpiperazine;
        (83) Methoxetamine;
        (84) 1-(Ethylamino)-2-phenylpropan-2-one (iso-
    ethcathinone).
    (e) Unless specifically excepted or unless listed in
another schedule, any material, compound, mixture, or
preparation which contains any quantity of the following
substances having a depressant effect on the central nervous
system, including its salts, isomers, and salts of isomers
whenever the existence of such salts, isomers, and salts of
isomers is possible within the specific chemical designation:
        (1) mecloqualone;
        (2) methaqualone; and
        (3) gamma hydroxybutyric acid.
    (f) Unless specifically excepted or unless listed in
another schedule, any material, compound, mixture, or
preparation which contains any quantity of the following
substances having a stimulant effect on the central nervous
system, including its salts, isomers, and salts of isomers:
        (1) Fenethylline;
        (2) N-ethylamphetamine;
        (3) Aminorex (some other names:
    2-amino-5-phenyl-2-oxazoline; aminoxaphen;
    4-5-dihydro-5-phenyl-2-oxazolamine) and its
    salts, optical isomers, and salts of optical isomers;
        (4) Methcathinone (some other names:
    2-methylamino-1-phenylpropan-1-one;
    Ephedrone; 2-(methylamino)-propiophenone;
    alpha-(methylamino)propiophenone; N-methylcathinone;
    methycathinone; Monomethylpropion; UR 1431) and its
    salts, optical isomers, and salts of optical isomers;
        (5) Cathinone (some trade or other names:
    2-aminopropiophenone; alpha-aminopropiophenone;
    2-amino-1-phenyl-propanone; norephedrone);
        (6) N,N-dimethylamphetamine (also known as:
    N,N-alpha-trimethyl-benzeneethanamine;
    N,N-alpha-trimethylphenethylamine);
        (7) (+ or -) cis-4-methylaminorex  ((+ or -) cis-
    4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);
        (8) 3,4-Methylenedioxypyrovalerone (MDPV);
        (9) Halogenated amphetamines and
    methamphetamines - any compound derived from either
    amphetamine or methamphetamine through the substitution
    of a halogen on the phenyl ring, including, but not
    limited to, 2-fluoroamphetamine, 3-
    fluoroamphetamine and 4-fluoroamphetamine; 
        (10) Aminopropylbenzofuran (APB):
    including 4-(2-Aminopropyl) benzofuran, 5-
    (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
    benzofuran, and 7-(2-Aminopropyl) benzofuran; 
        (11) Aminopropyldihydrobenzofuran (APDB):
    including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
    5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
    6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
    and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran; 
        (12) Methylaminopropylbenzofuran
    (MAPB): including 4-(2-methylaminopropyl)
    benzofuran, 5-(2-methylaminopropyl)benzofuran,
    6-(2-methylaminopropyl)benzofuran
    and 7-(2-methylaminopropyl)benzofuran. 
    (g) Temporary listing of substances subject to emergency
scheduling. Any material, compound, mixture, or preparation
that contains any quantity of the following substances:
        (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
    (benzylfentanyl), its optical isomers, isomers, salts, and
    salts of isomers;
        (2) N-[1(2-thienyl) methyl-4-piperidyl]-N-
    phenylpropanamide (thenylfentanyl), its optical isomers,
    salts, and salts of isomers.
    (h) Synthetic cathinones. Unless specifically excepted,
any chemical compound which is not approved by the United
States Food and Drug Administration or, if approved, is not
dispensed or possessed in accordance with State or federal law,
not including bupropion, structurally derived from
2-aminopropan-1-one by substitution at the 1-position with
either phenyl, naphthyl, or thiophene ring systems, whether or
not the compound is further modified in one or more of the
following ways:
        (1) by substitution in the ring system to any extent
    with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or
    halide substituents, whether or not further substituted in
    the ring system by one or more other univalent
    substituents. Examples of this class include, but are not
    limited to, 3,4-Methylenedioxycathinone (bk-MDA);
        (2) by substitution at the 3-position with an acyclic
    alkyl substituent. Examples of this class include, but are
    not limited to, 2-methylamino-1-phenylbutan-1-one
    (buphedrone); or
        (3) by substitution at the 2-amino nitrogen atom with
    alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by
    inclusion of the 2-amino nitrogen atom in a cyclic
    structure. Examples of this class include, but are not
    limited to, Dimethylcathinone, Ethcathinone, and
    a-Pyrrolidinopropiophenone (a-PPP); or .
    Any other synthetic cathinone which is not approved by the
United States Food and Drug Administration or, if approved, is
not dispensed or possessed in accordance with State or federal
law.
    (i) Synthetic cannabinoids or piperazines. Any synthetic
cannabinoid or piperazine which is not approved by the United
States Food and Drug Administration or, if approved, which is
not dispensed or possessed in accordance with State and federal
law.
(Source: P.A. 99-371, eff. 1-1-16; 100-201, eff. 8-18-17;
100-368, eff. 1-1-18; revised 10-5-17.)